CorMedix Inc. to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

CorMedix Inc. (Nasdaq: CRMD) announced that its management will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 11:30 am ET. The company focuses on developing therapeutic products to prevent and treat infectious and inflammatory diseases, notably its lead product DefenCath, designed to prevent bloodstream infections linked to central venous catheters in hemodialysis patients. DefenCath is FDA Fast Track designated and awaits NDA approval after addressing manufacturing deficiencies.

BERKELEY HEIGHTS, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will present a corporate overview at the Jefferies Virtual Healthcare Conference taking place on June 1 – 4, 2021.

Jefferies Virtual Healthcare Conference

Date:	Friday, June 4
Time:	11:30 am Eastern Time
Webcast:	https://wsw.com/webcast/jeff174/crmd/1840266

About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product (QIDP), and the NDA received priority review in recognition of its potential to address an unmet medical need. QIDP provides for an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also committed to conducting a clinical study in pediatric patients using a central venous catheter for hemodialysis when the NDA is approved, which will add an additional six months of marketing exclusivity when the study is completed. The Company received a Complete Response Letter from FDA stating that the NDA could not be approved until satisfactory resolution of deficiencies at the contract manufacturing facility, including in-process controls for the filling operation. CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. Neutrolin® is CE Marked and marketed in Europe and other territories as a medical device. For more information, visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
(617) 430-7576

FAQ

What date will CorMedix present at the Jefferies Virtual Healthcare Conference?

CorMedix will present on June 4, 2021.

What is the time of CorMedix's presentation at the conference?

The presentation is scheduled for 11:30 am Eastern Time.

What is DefenCath and its purpose?

DefenCath is an antibacterial and antifungal solution aimed at preventing bloodstream infections in hemodialysis patients.

What designation has the FDA given to DefenCath?

DefenCath has been designated as Fast Track and Qualified Infectious Disease Product (QIDP) by the FDA.

What is the current status of the NDA for DefenCath?

The NDA for DefenCath received a Complete Response Letter from the FDA due to manufacturing deficiencies.

How does the QIDP designation benefit DefenCath?

QIDP designation provides an additional five years of marketing exclusivity upon NDA approval.